<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510675</url>
  </required_header>
  <id_info>
    <org_study_id>OMZRIP1F</org_study_id>
    <nct_id>NCT04510675</nct_id>
  </id_info>
  <brief_title>Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT</brief_title>
  <official_title>A 6-Week, Randomized, Evaluator-Blinded, In Vivo Within Subject Repeat Test to Evaluate the Irritation and Sensitization Potential of Omeza Collagen Matrix in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeza, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeza, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to assess the sensitization potential of Omeza&#xD;
      Collagen Matrix compared to that of a negative control based on a Modified Human Repeat&#xD;
      Insult Patch Test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Actual">January 11, 2020</completion_date>
  <primary_completion_date type="Actual">January 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The trained skin evaluator and Investigator was blinded to the identity of the test materials. Test/control sites were randomized within participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Erythema</measure>
    <time_frame>21 days</time_frame>
    <description>Rated on a numeric scale from 0 - 3 (0: No visible reaction, +: Slight/patchy, 1: Mild, 2: Moderate, 3: Strong)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitisation</measure>
    <time_frame>30 minutes</time_frame>
    <description>Subjects had a rest period of 10-17 days, followed by challenge applications of each investigational product to naive sites for approximately 48 hours. Evaluation of response was measure by rating skin irritancy/erythema on a scale of 0-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitisation</measure>
    <time_frame>24 hours</time_frame>
    <description>Subjects had a rest period of 10-17 days, followed by challenge applications of each investigational product to naive sites for approximately 48 hours. Evaluation of response was measure by rating skin irritancy/erythema on a scale of 0-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitisation</measure>
    <time_frame>48 hours</time_frame>
    <description>Subjects had a rest period of 10-17 days, followed by challenge applications of each investigational product to naive sites for approximately 48 hours. Evaluation of response was measure by rating skin irritancy/erythema on a scale of 0-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitisation</measure>
    <time_frame>72 hours</time_frame>
    <description>Subjects had a rest period of 10-17 days, followed by challenge applications of each investigational product to naive sites for approximately 48 hours. Evaluation of response was measure by rating skin irritancy/erythema on a scale of 0-3</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Erythema</condition>
  <condition>Sensitisation</condition>
  <arm_group>
    <arm_group_label>Test Article</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Article</intervention_name>
    <description>Omeza Collagen Matrix</description>
    <arm_group_label>Test Article</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Negative Control</intervention_name>
    <description>Occlusive Patch of 0.9% sodium chloride, NaCl</description>
    <arm_group_label>Negative Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health, as assessed by medical history and brief dermal skin examination&#xD;
             of the application site (back);&#xD;
&#xD;
          -  Was fully informed of the risks of entering the study and was willing to provide&#xD;
             written consent to enter the study;&#xD;
&#xD;
          -  Was willing to follow study rules, which included: no sun exposure (for example; no&#xD;
             swimming, sunbathing, or tanning beds), avoided activities that would cause excessive&#xD;
             sweating, abstained from use of lotions, creams, or oils on the back area;&#xD;
&#xD;
          -  Was willing to not change current brand of personal care products such as soaps, body&#xD;
             washes, laundry detergents, body sprays, body spritzes, etc. while participating on&#xD;
             the study;&#xD;
&#xD;
          -  Was willing and able to practice an acceptable measure of contraception (i.e. birth&#xD;
             control medication for at least 3 months prior, condom with spermicide or birth&#xD;
             control injections,) during the study, if female of childbearing potential. To be&#xD;
             considered female of non-childbearing potential, subject must have had a hysterectomy,&#xD;
             tubal ligation, or had been post-menopausal for at least 1 year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant skin disease which contraindicated participation, including&#xD;
             psoriasis, eczema, atopic dermatitis, and active cancer;&#xD;
&#xD;
          -  Asthma that required medication;&#xD;
&#xD;
          -  Insulin-dependent diabetes;&#xD;
&#xD;
          -  Known immunological disorders such as HIV positive, AIDS and systemic lupus&#xD;
&#xD;
          -  erythematosus;&#xD;
&#xD;
          -  Treatment for any type of cancer within the last six months;&#xD;
&#xD;
          -  Routine use (as defined by using more than 3 days in a week) of any anti-inflammatory&#xD;
             drug (e.g., aspirin, ibuprofen, corticosteroids; 81 mg aspirin is acceptable),&#xD;
             immunosuppressive drugs, antihistamine medication (steroid nose drops and/or eye drops&#xD;
             are acceptable) or over-the-counter pain medication that was ingested in quantities&#xD;
             exceeding label instructions;&#xD;
&#xD;
          -  Use of topical drugs at patch site;&#xD;
&#xD;
          -  Pregnancy, lactation, or planning a pregnancy (confirmed by a urine pregnancy test&#xD;
             administered to females of childbearing potential);&#xD;
&#xD;
          -  Medical condition which, in the Investigator's judgement, made the subject&#xD;
&#xD;
          -  ineligible or placed the subject at undue risk;&#xD;
&#xD;
          -  Participation in any patch test for irritation or sensitization within the last four&#xD;
             weeks;&#xD;
&#xD;
          -  Dermatological aberrations in or around test sites which included sunburn, extremely&#xD;
             deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or&#xD;
             any other disfiguration of the test site;&#xD;
&#xD;
          -  Confirmed allergy to adhesives, bandages, or ingredients in OmezaTM Collagen Matrix;&#xD;
&#xD;
          -  History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PCR Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lori DeCaro</last_name>
    <role>Study Director</role>
    <affiliation>PCR Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PCR Corp</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 11, 2021</submitted>
    <returned>June 4, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

